JP2016537366A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537366A5
JP2016537366A5 JP2016531020A JP2016531020A JP2016537366A5 JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5 JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently selected
heterocyclyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537366A (ja
JP6494622B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065599 external-priority patent/WO2015073767A1/en
Publication of JP2016537366A publication Critical patent/JP2016537366A/ja
Publication of JP2016537366A5 publication Critical patent/JP2016537366A5/ja
Application granted granted Critical
Publication of JP6494622B2 publication Critical patent/JP6494622B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016531020A 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体 Expired - Fee Related JP6494622B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14
US61/904,116 2013-11-14
PCT/US2014/065599 WO2015073767A1 (en) 2013-11-14 2014-11-14 Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors

Publications (3)

Publication Number Publication Date
JP2016537366A JP2016537366A (ja) 2016-12-01
JP2016537366A5 true JP2016537366A5 (cg-RX-API-DMAC10.html) 2017-12-21
JP6494622B2 JP6494622B2 (ja) 2019-04-03

Family

ID=51952052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016531646A Expired - Fee Related JP6494624B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
JP2016531020A Expired - Fee Related JP6494622B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016531646A Expired - Fee Related JP6494624B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体

Country Status (9)

Country Link
US (3) US9273058B2 (cg-RX-API-DMAC10.html)
EP (2) EP3068784B1 (cg-RX-API-DMAC10.html)
JP (2) JP6494624B2 (cg-RX-API-DMAC10.html)
CN (2) CN105916855B (cg-RX-API-DMAC10.html)
AR (1) AR098414A1 (cg-RX-API-DMAC10.html)
ES (2) ES2718218T3 (cg-RX-API-DMAC10.html)
TW (1) TW201605859A (cg-RX-API-DMAC10.html)
UY (1) UY35834A (cg-RX-API-DMAC10.html)
WO (2) WO2015073767A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
WO2015129821A1 (ja) 2014-02-27 2015-09-03 国立大学法人東京大学 オートタキシン阻害活性を有する縮合ピラゾール誘導体
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3458455B1 (en) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
CA3038331A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
KR20200032702A (ko) * 2017-07-27 2020-03-26 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도
CA3073986A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CA3075880A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
AR113820A1 (es) 2017-11-01 2020-06-17 Bristol Myers Squibb Co Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) * 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3744718A4 (en) * 2018-06-01 2021-11-17 Adlai Nortye Biopharma Co., Ltd. HIGHLY ACTIVE CSF1R INHIBITOR CONNECTION
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
CA3126334A1 (en) 2019-01-11 2020-07-16 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
CA3126175A1 (en) * 2019-01-25 2020-07-30 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of 1,2,3-triazolo[1,5-a]pyrazines derivative and preparation method for crystal form
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
JP2023541465A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
TW202245772A (zh) * 2021-02-04 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法
WO2023147015A1 (en) * 2022-01-27 2023-08-03 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
EP4538275A1 (en) * 2022-06-13 2025-04-16 Shionogi & Co., Ltd Crystal of dihydropyridinone derivative or solvate thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024967A2 (en) * 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7402672B2 (en) * 2003-12-11 2008-07-22 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN103582482B (zh) 2011-03-02 2016-10-12 利德探索中心有限公司 药学活性的二取代的三嗪衍生物
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Similar Documents

Publication Publication Date Title
JP2016537366A5 (cg-RX-API-DMAC10.html)
JP2016537369A5 (cg-RX-API-DMAC10.html)
JP6474068B2 (ja) 2−アミノピリミジン系化合物およびその薬物組成物と使用
JP2016507502A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2018522879A5 (cg-RX-API-DMAC10.html)
JOP20190092A1 (ar) عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP2018522866A5 (cg-RX-API-DMAC10.html)
JP2018519245A5 (cg-RX-API-DMAC10.html)
JP2018516238A5 (cg-RX-API-DMAC10.html)
JP2016515561A5 (cg-RX-API-DMAC10.html)
JP2017518344A5 (cg-RX-API-DMAC10.html)
JP2017511360A5 (cg-RX-API-DMAC10.html)
JP2013532652A5 (cg-RX-API-DMAC10.html)
JP2016508135A5 (cg-RX-API-DMAC10.html)
JP2012532112A5 (cg-RX-API-DMAC10.html)
JP2016517857A5 (cg-RX-API-DMAC10.html)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
JP2014513139A5 (cg-RX-API-DMAC10.html)
JP2018522867A5 (cg-RX-API-DMAC10.html)
RU2016134751A (ru) Соединения
RU2012130929A (ru) Гетероциклические соединения в качестве ингибиторов янус-киназы
RU2010143455A (ru) Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов
JP2014506582A5 (cg-RX-API-DMAC10.html)
JP2016531868A5 (cg-RX-API-DMAC10.html)